Arcturus Shares Plunge After Mixed Results in Cystic Fibrosis Spray Trial

Arcturus Therapeutics shares drop sharply after interim trial data on its inhaled mRNA therapy for cystic fibrosis show mixed results—some signs of mucus reduction but limited lung function improvement.